Last reviewed · How we verify

NCT04792814

Cell Salvage and Retrograde Autologous Priming

Completed Last updated 11 March 2021
What this trial tests

trial in Surgery in 200 participants. Completed in 31 October 2019.

Timeline
1 June 2018
Primary endpoint
31 October 2019
31 October 2019

Quick facts

Lead sponsorUniversity Hospital Schleswig-Holstein
StatusCompleted
Study typeOBSERVATIONAL
Enrollment200
Start date1 June 2018
Primary completion31 October 2019
Estimated completion31 October 2019
Sites2 locations across Germany

Conditions studied

Sponsor

University Hospital Schleswig-Holstein

Who can join

18 and older, any sex, with Surgery or Hemodynamic Instability. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In recent years Patient Blood Management (PBM) has developed into a multifactorial and interdisciplinary concept that focuses on individualized and optimized hemotherapy. Of course, this also applies to the cardiac surgery area (1). In this context, the quality of the intraoperative PBM can be represented by patients scheduled for isolated coronary artery bypass grafting (CABG) and isolated aortic valve replacement (AVR). In a prospective, observational "before-and-after" protocol, the investigators analysed the impact of the combined use of retrograde autologous priming (RAP) and cell salvage on intraoperative usage of red blood cell concentrates (RBC) (2).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Surgery

Currently open trials in the same condition.

Other University Hospital Schleswig-Holstein trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04792814.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing